Literature DB >> 9790686

Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability.

J P Clancy1, J S Hong, Z Bebök, S A King, S Demolombe, D M Bedwell, E J Sorscher.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is a member of the traffic ATPase family that includes multiple proteins characterized by (1) ATP binding, (2) conserved transmembrane (TM) motifs and nucleotide binding domains (NBDs), and (3) molecular transport of small molecules across the cell membrane. While CFTR NBD-1 mediates ATP binding and hydrolysis, the membrane topology and function of this domain in living eukaryotic cells remains uncertain. In these studies, we have expressed wild-type CFTR NBD-1 (amino acids 433-586) or NBD-1 containing the DeltaF508 mutation transiently in COS-7 cells and established that the domain is situated across the plasma membrane by four independent assays; namely, extracellular chymotrypsin digestion, surface protein biotinylation, confocal immunofluorescent microscopy, and functional measurements of cell membrane anion permeability. Functional studies indicate that basal halide permeability is enhanced above control conditions following wild-type or DeltaF508 NBD-1 expression in three different epithelial cell lines. Furthermore, when clinically relevant CFTR proteins truncated within NBD-1 (R553X or G542X) are expressed, surface localization and enhanced halide permeability are again established. Together, these findings suggest that isolated CFTR NBD-1 (with or without the DeltaF508 mutation) is capable of targeting the epithelial cell membrane and enhancing cellular halide permeability. Furthermore, CFTR truncated at position 553 or 542 and possessing the majority of NBD-1 demonstrates surface localization and also confers increased halide permeability. These findings indicate that targeting to the plasma membrane and assumption of a transmembrane configuration are innate properties of the CFTR NBD-1. The results also support the notion that components of the halide-selective pore of CFTR reside within NBD-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790686     DOI: 10.1021/bi980436f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers.

Authors:  Zsuzsa Bebok; James F Collawn; John Wakefield; William Parker; Yao Li; Karoly Varga; Eric J Sorscher; J P Clancy
Journal:  J Physiol       Date:  2005-10-06       Impact factor: 5.182

2.  DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.

Authors:  S M Rowe; L C Pyle; A Jurkevante; K Varga; J Collawn; P A Sloane; B Woodworth; M Mazur; J Fulton; L Fan; Y Li; J Fortenberry; E J Sorscher; J P Clancy
Journal:  Pulm Pharmacol Ther       Date:  2010-03-10       Impact factor: 3.410

3.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.

Authors:  Steven M Rowe; Peter Sloane; Li Ping Tang; Kyle Backer; Marina Mazur; Jessica Buckley-Lanier; Igor Nudelman; Valery Belakhov; Zsuzsa Bebok; Erik Schwiebert; Timor Baasov; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2011-07-22       Impact factor: 4.599

4.  Restoration of W1282X CFTR activity by enhanced expression.

Authors:  Steven M Rowe; Karoly Varga; Andras Rab; Zsuzsa Bebok; Kevin Byram; Yao Li; Eric J Sorscher; John P Clancy
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

5.  Severed molecules functionally define the boundaries of the cystic fibrosis transmembrane conductance regulator's NH(2)-terminal nucleotide binding domain.

Authors:  K W Chan; L Csanády; D Seto-Young; A C Nairn; D C Gadsby
Journal:  J Gen Physiol       Date:  2000-08       Impact factor: 4.086

6.  Purification, characterization, and expression of CFTR nucleotide-binding domains.

Authors:  J P Clancy; Z Bebök; E J Sorscher
Journal:  J Bioenerg Biomembr       Date:  1997-10       Impact factor: 3.853

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.